ADCY1 and atrial fibrillation: The IP3 signalling pathway has therefore been identified as a potential atrial-specific target for the treatment of AF (Tinker et al., 2016), and the existence of a downstream AC1 dependent pathway in atrial and SAN tissue could therefore hold promise for the development of pharmacological interactions that selectively target cardiac AC1.